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Background: There is a growing body of evidence that mental distress and disorder are common among people
with lower limb lymphoedema, although no research has been conducted on this subject in Rwanda.
Methods: This research was embedded within a mapping study to determine the national prevalence and geo-
graphical distribution of podoconiosis in Rwanda. Using a cluster sampling design, adult members of house-
holds within 80 randomly selected sectors in all 30 districts of Rwanda were first screened and 1143 patients
were diagnosed with either podoconiosis (n=914) or lower limb lymphoedema of another cause (n=229). These
1143 participants completed the Patient Health Questionnaire (PHQ)-9 to establish the prevalence of depressive
symptoms.
Results: Overall, 68.5% of participants reported depressive symptoms- 34.3% had mild depressive symptoms,
24.2% had moderate, 8.8% moderately severe and 1.2% severe depressive symptoms. The mean PHQ-9 score
was 7.39 (SD=5.29) out of a possible 0 (no depression) to 27 (severe depression). Linear regression showed
unemployment to be a consistently strong predictor of depressive symptoms; the other predictors were region
(province), type of lymphoedema and, for those with podoconiosis, female gender, marital status and disease
stage.
Conclusions: Levels of depressive symptoms were very high among people with lower limb lymphoedema in
Rwanda, which should be addressed through holistic morbidity management and disability prevention services
that integrate mental health, psychosocial and economic interventions alongside physical care.
Keywords: depression, lymphoedema, mental health, morbidity, prevalence, Rwanda
Introduction
Podoconiosis is a neglected tropical disease (NTD) that is com-
mon among barefoot subsistence farmers who have long-term
exposure to irritant red clay tropical soils1 in areas where
ancient volcanic deposits have weathered at high altitude2
and where there is heavy rainfall. Podoconiosis results in lower
limb lymphoedema, i.e. swelling of the lower leg and feet, as
do other NTDs such as lymphatic filariasis (LF) and leprosy,
which—unlike podoconiosis—are caused by parasites and Bacilli,
respectively.
Rwanda is one of the countries where podoconiosis has only
recently been mapped, with an estimated overall prevalence of
68.5 per 100 000 people or 0.069%, which amounts to around
6429 people with podoconiosis, spread widely across Rwanda.3
Other countries in which podoconiosis is widespread include
Ethiopia, Cameroon, Kenya, Tanzania and Uganda,4 with approx-
imately 4 million cases worldwide across at least 32 countries.4,5
Globally, lymphoedema caused by either LF or leprosy occurs in
around 15 million6 and 200 0007 people, respectively.
In addition to the physical disability associated with lower
limb lymphoedema, there is a largemental health and psychoso-
cial burden for patients as well as their families and communi-
ties, which can includemental distress,8 depression,9 stigma10–14
and loss of economic productivity.15–17 For example, a recent
study in Cameroon by our group found that 38.6% of people
with podoconiosis or lymphoedema of another cause displayed
© The Author(s) 2020. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. This is an Open Access
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at least mild depressive symptoms.18 Other previous research
reported that 12.6%of podoconiosis patients in northern Ethiopia
had depressive symptoms and that 5.2% were at risk of sui-
cide, compared with only 0.7% and 0.4% of their healthy neigh-
bours, respectively.9 In Nigeria, 20% of people with LF have been
reported to have depression compared with 3.1–5.2% in the
general adult population.19 Mental distress has also been found
to be significantly higher among people with podoconiosis in
Ethiopia compared with healthy controls.8 What is more, a global
study on the burden of depression associated with LF estimated
that the psychological and emotional effects of LF were dou-
ble those of the physical health burden linked to the disease.20
This comorbidity with mental disorder and overall reduced men-
tal well-being, together with the associated stigma that is com-
monly experienced by people with lower limb lymphoedema,
can act as a major barrier to accessing and adhering to morbid-
ity management and disability prevention (MMDP) services.21,22
However, research on this subject is still in its infancy and—to
our knowledge—no study on the mental health implications of
podoconiosis or lower limb lymphoedema of another cause has
to date been conducted in Rwanda.
This study aims to address this gap by reporting on the
prevalence of depressive symptoms among people with lower
limb lymphoedema in Rwanda, as well as providing comparisons
between people affected by podoconiosis and those with lower
limb lymphoedema of another cause.
Materials and Methods
Design
This research was part of a larger population-based country-
wide cross-sectional survey that aimed to determine the national
prevalence and geographical distribution of podoconiosis in
Rwanda.3 The larger mapping study used a cluster sampling
design, whereby at least two sectors (proportional to the num-
ber of sectors per district to adjust for sector size) were randomly
selected from within each of the 30 districts of Rwanda. The
research reported here was embedded within the larger map-
ping study and aimed to estimate the prevalence of depressive
symptoms among those people who were diagnosed with either
podoconiosis or lower limb lymphoedema of another cause dur-
ing the larger study.
Setting
The study was conducted in 80 randomly selected sectors (out
of a possible 416) within all 30 districts of Rwanda. The screening
stage took place within participants’ households, while the sec-
ond verification/diagnosis stage was conducted in a private room
at the nearest public health centre.
Sample
For the larger mapping study, all adults within randomly selected
sectors aged >15 y who had lived in the area for at least 10 y (to
omit those individuals who might have acquired the leg swelling
elsewhere) were invited to participate, excluding those who were
not able to respond, for example, due to terminal illness or a
severemental disorder. The research reported here involved 1143
participants who were identified as having either podoconiosis or
lower limb lymphoedema of another cause in the larger study.
Procedure
As part of the larger mapping study, during the first screening
stage, all households in the randomly selected sectors were vis-
ited in June or July 2017 by trained community health work-
ers who documented residence, gender, age and whether leg
swelling of any type was present or not, with people who showed
swelling of one or both lower limbs being recorded as sus-
pected podoconiosis cases. In total, 1360 612 individuals were
screened, of whom 640 882 were men (47.1%) and 719 730
were women (52.9%). Of these, 1143 (0.08%) were identified
to be possible podoconiosis cases, i.e. individuals with lower
limb lymphoedema.
In the second stage, during November and December 2017,
the 1143 suspected cases were verified as either podoconiosis
(n=914; 80.0%) or lower limb lymphoedema of another cause
(n=229; 20.0%) by locally recruited expert clinical diagnostic
teams, each of which included four health workers, a medical
doctor, a nurse, a laboratory technician and a team leader, using
procedures that had previously been employed during amapping
study in Cameroon.18,23 All individuals with suspected podoco-
niosis were physically examined, and a diagnosis of podoconiosis
or lymphoedema of another cause was established through this
physical examination, as well as via history and disease-specific
tests. A podoconiosis case was defined as a person residing in
the surveyed district for at least 10 y who had bilateral, asym-
metrical lymphoedema of the lower limb lasting for >1 y, nega-
tive Filariasis Test Strip (Alere; Scarborough, ME, USA) and Wb123
tests, and a history of any of the signs and symptoms associated
with podoconiosis (for more details on this, including informa-
tion on the aetiologies of those with lymphoedema of another
cause, see the larger mapping study conducted by Deribe et al.3).
For disease staging of podoconiosis, the staging system of Tekola
et al. (2008)24 was used, where 1 denotes the least severe and 5
the most severe disease stage. In addition, participants’ sociode-
mographic data and information on disease characteristics were
collected via questionnaires, including individual-level data on
age, gender, education, occupation, place of residence, shoe-
wearing and foot hygiene practices, age at onset of swelling, fam-
ily member(s) (living or dead) with a history of leg swelling, the
type of swelling (ascending upwards from the foot, or descend-
ing down the leg from the upper leg or groin area), self-reported
chronic illness such as heart disease, kidney disease or diabetes,
clinical diagnoses of known causes of lymphoedema (such as
congenital disorders, leprosy and postoperative lymphoedema)
and the cooccurrence of swelling in other parts of the body such
as the hands, face and scrotum (hydrocele), household data on
water, sanitation and hygiene, as well as geographical coordi-
nates from surveyed communities via smartphones.
Furthermore, all 1143 participants identified as having lower
limb lymphoedema were administered the Patient Health Ques-
tionnaire (PHQ)-9 as a measure of depressive symptoms. The
PHQ-9 has been used, tested and validated as a measure of
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nine questions, which ask respondents how often they have been
affected by a set of nine problems over the last 2 wk, for example,
having little interest or pleasure in doing things, feeling tired or
having little energy, having a poor appetite or overeating and
having trouble concentrating. There is also an additional question
(which is not part of the overall scoring) that asks the respondent
how difficult any depression symptomsmade it for them to com-
plete various activities of daily life. The PHQ-9 scores were classi-
fied in this study according to categories that have been widely
used,9 as follows: no depression (0–4), mild (5–9), moderate (10–
14), moderately severe (15–19) and severe depression (20–27).
It is these PHQ-9 results that this paper reports on (see Deribe
et al.3 for the findings of the larger mapping study).
All study materials were translated into and administered in
the Kinyarwanda language. Data were collected using the LINKS
software package (version 1.4.2; Secure Data Kit, Atlanta, GA,
USA) installed onto Android smartphones. This required data col-
lectors to complete all compulsory questions before being able to
move on to the next one.
Ethical approval was obtained as part of the larger map-
ping study from the Rwanda National Ethics Committee and
the Brighton & Sussex Medical School Research Governance and
Ethics Committee, Brighton, UK. All participants either gave their
written informed consent to take part in the study or, where
participants were illiterate, they confirmed their consent via a
thumbprint and a signature from a literate witness. Where par-
ticipants were aged <18 y, they gave their consent verbally and
a parent or guardian provided written consent.
Analysis
Data analyses were conducted using IBM SPSS 25 and 26 (IBM
Corp; Armonk, New York, USA). A significance level of 0.05 was
employed for all analyses. Descriptive analyses (frequencies and
percentages for categorical variables and means with standard
deviations for continuous variables) were used to present the
sociodemographic and disease characteristics of participants.
χ2 (categorical variables; using Fisher’s exact test where the
expected cell counts were <10) and independent t-tests (con-
tinuous variables) were employed to assess whether there were
any differences in sociodemographic and disease characteristics
and PHQ-9 scores between participants who had podoconiosis vs
those who had lymphoedema of another cause.
To determine the prevalence of depressive symptoms, the
mean total PHQ-9 score was calculated. Cronbach’s alpha was
computed as a measure of the internal consistency of the PHQ-
9 to assess whether the PHQ-9 was able to reliably measure
depressive symptoms within this population; a higher Cronbach’s
alpha score indicates a higher likelihood that all items in the scale
measure the same underlying construct.
Standard multivariate linear regression was employed, to
assess the association between participants’ sociodemographic
and disease characteristics and depressive symptoms. Two mul-
tivariate regression models were run; in the first, all 1143 par-
ticipants were included, and in the second only those partici-
pants diagnosed with podoconiosis (n=914) were included so
that disease stage could be added into the model (as these
data were not available for participants with lymphoedema of
another cause). PHQ-9 score (depressive symptoms) was the
dependent variable in both models, and the following factors
were included as independent variables: age (continuous vari-
able), gender (male/female), geographical region (five provinces),
marital status (married/single/divorced/widowed), employment
status (employed/unemployed), literacy (literate/illiterate), type
of lymphoedema (podoconiosis/lymphoedemaof another cause)
(first model only) and stage of disease (stage 1/stage 2/stage 3
and above) (second model only). No variable selection was per-
formed and independent variables included in the models were
chosen based on prior literature and expert knowledge. Where
any independent variables had categories with <5% of partici-
pants, these were regrouped so that all categories contained at
least 5% of participants. Dummy variables were created in SPSS
for those categorical variables with >2 levels before they were
entered into the regression models. Assumptions of both regres-
sion models were checked, including homoscedasticity, multi-
collinearity, independence and normality of residuals; outliers
were also examined.
Results
Table 1 shows the sociodemographic and disease characteris-
tics of the 1143 people identified as having either podoconiosis
(n=914; 80.0%) or lower limb lymphoedema of another cause
(n=229; 20.0%). The only two of the sociodemographic or dis-
ease characteristics listed in Table 1 for which there was a sta-
tistically significant difference between those who had podoco-
niosis compared with those who had lymphoedema of another
cause were employment (χ2=12.12, d.f.=1; p < 0.0001) and
occupation (χ2=17.42, d.f.=8; p=0.026). Those with podoconio-
sis were more likely not to be working (11.1%) than those with
lymphoedema of another cause (3.5%). In accordance with this,
for those occupation categories related to being in work (farmer
and ‘employed other’), there were less people with podoconio-
sis proportionally to those with lymphoedema of another cause
(Table 1).
In regard to depressive symptoms, the mean PHQ-9 score
among all 1143 participants was 7.39 (SD=5.29), ranging
between 0 and 24 (out of a possible maximum score of 27, which
denotes very severe depressive symptoms). For the additional
question on the PHQ-9, which asks how difficult any symptoms
of depression made it for the respondent to carry out their work,
take care of things at home, or get along with other people, the
mean score was 1.68 (SD=0.77), on a scale of 0 (not difficult
at all), 1 (somewhat difficult), 2 (very difficult) and 3 (extremely
difficult). Cronbach’s alpha for the PHQ-9 was 0.8, which is con-
sidered to demonstrate good internal consistency.
Using a PHQ-9 score of ≥5 as cut-off, 783 people (68.5%)
with lower limb lymphoedema (n=1143) were classified as
having at least mild depressive symptoms. Using a PHQ-9 score
of ≥10 as a screening indicator for major depressive disorder,
391 people (34.2%) were classified as being in this category, with
115 (10.0%) having either moderately severe or severe depres-
sive symptoms (Table 2). Among people who scored above the
screening cut-off score of 10, the mean PHQ-9 score was 13.34
(SD=2.99).
Both multivariate standard linear regression models were
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Table 1. Sociodemographic and disease characteristics of people with lower limb lymphoedema in Rwanda
Total Podoconiosis Lymphoedema
Characteristics (n=1143) (n=914) of another cause (n=229)
Gender
Male 359 (31.4%) 276 (30.2%) 83 (36.2%)
Female 784 (68.6%) 638 (69.8%) 146 (63.8%)
Age, mean in years 53.41 (SD=17.56) 53.03 (SD=17.47) 54.93 (SD=17.88)
Region (province)
Kigali 35 (3.1%) 26 (2.8%) 9 (3.9%)
Northern 245 (21.4%) 195 (21.3%) 50 (21.8%)
Eastern 281 (24.6%) 223 (24.4%) 58 (25.3%)
Southern 282 (24.7%) 239 (26.1%) 43 (18.8%)
Western 300 (26.2%) 231 (25.3%) 69 (30.1%)
Marital status
Married 546 (47.8%) 432 (47.3%) 114 (49.8%)
Widowed 323 (28.3%) 257 (28.1%) 66 (28.8%)
Single 185 (16.2%) 155 (17.0%) 30 (13.1%)
Divorced 89 (7.8%) 70 (7.7%) 19 (8.3%)
Religion
Christian 1123 (98.3%) 898 (98.2%) 225 (98.3%)
Muslim 10 (0.9%) 7 (0.8%) 3 (1.3%)
Other 10 (0.9%) 9 (1.0%) 1 (0.4%)
Level of education
No formal education 797 (69.7%) 642 (70.2%) 155 (67.7%)
Primary school 319 (27.9%) 249 (27.2%) 70 (30.6%)
Secondary school 20 (1.7%) 19 (2.1%) 1 (0.4%)
Tertiary education 7 (0.6%) 4 (0.4%) 3 (1.3%)
Literate
Yes 379 (33.2%) 293 (32.1%) 86 (37.6%)
No 764 (66.8%) 621 (67.9%) 143 (62.4%)
Employment
Yes 1034 (90.5%) 813 (88.9%) 221 (96.5%)
No* 109 (9.5%) 101 (11.1%) 8 (3.5%)
Occupation
Farmer 1007 (88.1%) 793 (86.8%) 214 (93.4%)
Employed other (non-farmer) 27 (2.4%) 20 (2.2%) 7 (3.1%)
Student 11 (1.0%) 11 (1.2%) 0
Jobless 91 (8.0%) 84 (9.2%) 7 (3.1%)
Retired 7 (0.6%) 6 (0.7%) 1 (0.4%)
Mean number of years in current location 47.82 (SD=19.13) 47.59 (SD=19.21) 48.76 (SD=18.82)
Family member with history of leg swelling
Yes 481 (42.1%) 390 (42.7%) 91 (39.7%)
No 662 (57.9%) 524 (57.3%) 138 (60.3%)
Disease stage**
Stage 1 N/A 274 (30.0%) N/A
Stage 2 443 (48.5%)
Stages 3–5 197 (21.6%)
* This includes students and retired participants.
** The staging system by Tekola et al. (2008)24 was used, where 1 denotes the least severe disease stage and 5 marks the most severe disease
stage.
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Table 2. Depressive symptoms reported by people with lower limb lymphoedema in Rwanda
Depressive symptoms Total Podoconiosis Lymphoedema
(based on PHQ-9 scores) (n=1143) (n=914) of another cause (n=229)
Mean (SD) 7.39 (5.29) 7.25 (5.13) 7.95 (5.86)
No depression (0–4) 360 (31.5%) 293 (32.1%) 67 (29.3%)
Mild (5–9) 392 (34.3%) 316 (34.6%) 76 (33.2%)
Moderate (10–14) 276 (24.1%) 225 (24.6%) 51 (22.3%)
Moderately severe (15–19) 101 (8.8%) 72 (7.9%) 29 (12.7%)
Severe (20–27) 14 (1.2%) 8 (0.9%) 6 (2.6%)
Table 3. Multiple regression analysis for all participants with lower limb lymphoedema in Rwanda (n=1143)
PHQ-9 B 95% CI for B SE B ß R2 Adj-R2
Model 0.04 0.03***
Constant 4.92*** 2.99 to 6.84 0.98
Age 0.02 −0.002 to 0.04 0.01 0.07
Gender (male: reference group/female) 0.36 −0.37 to 1.08 0.37 0.03
Region (reference group: Eastern)
Kigali 0.94 −0.91 to 2.78 0.94 0.03
Northern 0.43 −0.48 to 1.33 0.46 0.03
Southern 0.71 −0.16 to 1.58 0.44 0.06
Western 1.15** 0.30 to 2.01 0.44 0.10**
Marital status (reference group: married)
Single 0.62 −0.37 to 1.61 0.50 0.04
Divorced 0.77 −0.43 to 1.97 0.61 0.04
Widowed 0.64 −0.19 to 1.48 0.42 0.06
Employed (yes: reference group/no) 1.73*** 0.67 to 2.80 0.54 0.10***
Literate (yes: reference group/no) 0.61 −0.06 to 1.28 0.34 0.05
Podoconiosis (yes/no: reference group) −0.84* −1.61 to −0.08 0.39 −0.06*
Model=‘Enter’ method in SPSS; B=unstandardized regression coefficient; SE B=standard error of the coefficient; ß=standardized coefficient;
R2=coefficient of determination; Adj-R2=adjusted R2. *p<0.05; **p<0.01; ***p<0.001.
although both models were only able to account for a small
amount of the variance in depressive symptoms (Tables 3 and 4).
The only variables that proved to be significant predictors for
depressive symptoms in both of the models that were run were
(1) unemployment, which strongly predicted depressive symp-
toms in both models (Tables 3 and 4), i.e. participants who were
not in work had significantly higher PHQ-9 scores on average than
those who were in work (when including all 1143 participants,
themean PHQ-9 score for people not in work was 9.02 [SD=5.63]
compared with a mean of 7.22 [SD=5.23] for people who were
working), and (2) region—specifically, participants in Western
Province reported significantly more depressive symptoms than
those in Eastern Province (mean=7.88, SD=5.02 vs mean=6.77,
SD=5.35, respectively, when including all 1143 participants; for
reference, the mean PHQ-9 scores for the other three provinces
were: Kigali [mean=7.69, SD=5.60], Northern [mean=7.30,
SD=5.81] and Southern [mean=7.54, SD=5.0], none of which
were significantly different from Eastern Province).
In addition, in the regression model that was run with all
participants (n=1143), the type of lymphoedema significantly
predicted depressive symptoms, whereby those with lym-
phoedema of another cause had higher levels of depressive
symptoms on average than those with podoconiosis (Tables 2
and 3).
In the model that was run with people affected by podoco-
niosis only (n=914) (Table 4), additional variables that were pre-
dictive of depressive symptoms (as well as unemployment and
region) were: female gender (women had mean PHQ-9 scores
of 7.58 [SD=5.19] compared with mean PHQ-9 scores of 6.51
[SD=4.93] amongmen);marital status—specifically, participants
whowere divorced (mean PHQ-9=8.54, [SD=4.12]) andwidowed
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Table 4. Multiple regression analysis for participants with podoconiosis in Rwanda (n=914)
PHQ-9 B 95% CI for B SE B ß R2 Adj-R2
Model 0.06 0.05***
Constant 4.13*** 2.08 to 6.17 1.04
Age 0.02 −0.01 to 0.04 0.01 0.05
Gender (male: reference group/female) 0.82* 0.05 to 1.62 0.41 0.07*
Region (reference group: Eastern)
Kigali 1.37 −0.69 to 3.42 1.05 0.04
Northern 0.36 −0.62 to 1.34 0.05 0.03
Southern 0.90 −0.02 to 1.82 0.47 0.08
Western 1.26** 0.32 to 2.19 0.48 0.11**
Marital status (reference group: married)
Single 0.71 −0.34 to 1.75 0.53 0.05
Divorced 1.78** 0.47 to 3.08 0.67 0.09**
Widowed 0.94* 0.04 to 1.84 0.46 0.08*
Employed (yes: reference group/no) 1.75*** 0.67 to 2.82 0.55 0.11***
Literate (yes: reference group/no) 0.54 −0.19 to 1.28 0.37 0.05
Disease stage (reference group: stage 3 and above)
Stage 1 −0.78 −1.72 to 0.17 0.48 −0.07
Stage 2 −1.31** −2.18 to −0.45 0.44 −0.13**
Model=‘Enter’ method in SPSS; B=unstandardized regression coefficient; SE B=standard error of the coefficient; ß=standardized coefficient;
R2=coefficient of determination; Adj-R2=adjusted R2. *p<0.05; **p<0.01; ***p<0.001.
symptoms on average that those who were married (mean PHQ-
9=6.49 [SD=5.09]) (for reference, themean PHQ-9 score for peo-
ple who were single was 7.30 [SD=5.2], but this was not sig-
nificantly different compared with being married); and disease
stage, i.e. those with stage 3 or higher podoconiosis had signif-
icantly higher levels of depressive symptoms on average (mean
PHQ-9=8.03 [SD=5.59]) than those with stage 2 podoconiosis
(mean PHQ-9=6.96 [SD=5.17]) (for reference, people with stage
1 podoconiosis had a mean PHQ-9 score of 7.17 [SD=4.67], but
this score was not significantly different compared with stage
3 or higher).
Discussion
Our study found very high levels of depressive symptoms among
people with lower limb lymphoedema in Rwanda, both for
podoconiosis and lymphoedema of another cause. Over two-
thirds of participants reported at leastmild depressive symptoms.
A quarter showed moderate depressive symptoms and every
10th participant displayed moderately severe or severe depres-
sive symptoms, indicating that around a third of participants
fit the screening classification for major depressive disorder. In
terms of how this affected functioning, on average, participants
considered depressive symptoms to make their daily activities
somewhat to very difficult.
These figures are higher than those that some prior stud-
ies in other countries have reported for people with lower limb
lymphoedema. For instance, our previous study in Cameroon,
which employed a very similar design to the research reported
in this paper, found that 38.6% of people with lower limb lym-
phoedema displayed at least mild depressive symptoms.18 Stud-
ies in northern Ethiopiawith podoconiosis patients9 and in Nigeria
with LF patients19 reported rates of 12.6% and 20% for depres-
sion, respectively. One partial explanation for the higher figures
in our Rwandan studymay be that rates of depressive symptoms
within the general population, even in those without chronic dis-
ease, might be higher in Rwanda than elsewhere because a large
part of the population who survived the 1994 genocide are still
experiencing mental disorders such as depression, panic disor-
der and post-traumatic stress disorder27; indeed, a recent nation-
widemental health survey in Rwanda estimated prevalence rates
for depression to be 11.9% in the general population and 35%
among genocide survivors,27 while the aforementioned studies
from Ethiopia9 and Nigeria19 reported depression rates of 0.7%
and 3.1–5.2% among healthy neighbours and the general pop-
ulation, respectively. Another factor may be that some of the
other studies already mentioned used more rigorous methods
to establish depression rather than simply reporting depressive
symptoms as in our study; for example, in the Ethiopian study,
the PHQ-9 was administered at two time points 2 wk apart and
depression was only deemed to be present if indicated at both
time points, resulting in more conservative estimates.9 In line
with this, a recent study by our group in northern Ethiopia that
used the PHQ-9 at one time point found even higher rates of
depressive symptoms (of 86.5%) among people with podoconio-
sis, LF and leprosy28 compared with the Rwandan study reported
here. Nevertheless, given that levels of depressive symptoms in
the Rwandan study appear to be far higher than those for the
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lower limb lymphoedema in Rwanda face a larger mental health
burden.
We found that unemployment was a consistently strong
predictor for depressive symptoms among people with lower
limb lymphoedema in Rwanda. This is in line with previous
research, which has also reported unemployment as being sig-
nificantly associated with depressive symptoms or depression,
including among people with podoconiosis and lower limb lym-
phoedema of another cause in Cameroon18 and among people
with LF in Nigeria.19 However, as highlighted previously,18 causal-
ity between unemployment and depressive symptoms for peo-
ple with lower limb lymphoedema cannot be established based
on these studies due to their cross-sectional design. It would be
interesting and helpful for this association to be explored further
in future research.
Other variables that we found to be predictors for depres-
sive symptoms in the regression models that we ran were region
(depressive symptoms were higher among people in Rwanda’s
Western Province compared with Eastern Province), the type of
lymphoedema (participants with lower limb lymphoedema of
another cause reported higher levels of depressive symptoms
than those with podoconiosis) and, for podoconiosis patients
only, female gender, marital status (those who were divorced or
widowed had higher levels of depressive symptoms than those
who were married) and disease stage (those with stage 3 or
higher podoconiosis reported more depressive symptoms). Our
findings on female gender and disease stage are consistent with
a previous study from Ethiopia, which reported that mental dis-
tress was higher among women with podoconiosis compared
with men and that mental distress was lowest among those
with the middle stages of podoconiosis (although the sample
size was not sufficiently large to adequately test this)29; the
same result was found in our sample. Conversely, another prior
study in Ethiopia found that the stage of disease had no impact
on depression scores for people affected by podoconiosis.30 In
regard to region, in keeping with our findings, the recent Rwanda
Mental Health Survey reported that depressionwas higher among
genocide survivors fromWestern Province (along with those from
Kigali and Southern Province) compared with those from Eastern
Province (alongwith those fromNorthern Province)27; the reasons
for this are not clear and should be explored, along with further
investigation of those other factors mentioned above that may
contribute to levels of depressive symptoms among people with
podoconiosis and lower limb lymphoedema of another cause.
The linear regression models that we employed were only
able to account for a very small part of the variance in depres-
sive symptoms. Important predictors for depressive symptoms
among this population group in Rwanda were therefore absent
from the model. Based on findings from prior research with other
populations in Rwanda, possible factors that may be important
specifically within the Rwandan context as predictors of depres-
sive symptoms and that were not included within our model
could be experiences of past traumatic experiences and grief
linked to the genocide against the Tutsi in 1994,31,32 poverty
andmarginalisation32 and functional impairment.33 Other impor-
tant factors may include a family history of mental illness,29 dis-
ability30 and experience of stigma.13,29 It is plausible—although
untested—that these factors may also be predictive of depres-
sive symptoms among people with lower limb lymphoedema
in Rwanda. Future research to explore these interactions further
among people with lymphoedema would be helpful.
Our study has several limitations, in addition to the cross-
sectional design already mentioned and the limited ability of the
regression models to explain depressive symptoms in this sam-
ple. Another weakness was that wewere unable to include a con-
trol group as a comparator for depressive symptoms, for exam-
ple, healthy neighbours, as this was beyond the scope of the
larger mapping study within which this research was embedded.
A further limitation of our study was the way in which depressive
symptoms were measured, which may have led to a bias in the
reporting of depressive symptoms, including that the psychome-
tric properties of the PHQ-9 have not been established in this par-
ticipant group (although the scale has been tested, validated and
used in a wide range of populations) and that the methods used
tomeasure depressive symptomswere not as rigorous as in other
studies (see above), whichmay have resulted in an over-reporting
of depressive symptoms. Indeed, recent systematic review evi-
dence recommends use of the PHQ-9 for literate populations, but
does not support its use so strongly among non-literate popu-
lations,26 as was the case in our study where only one-third of
participants could read and write. Conversely, people with such
severe mental disorders that they were not able to respond were
excluded from the current study, which could potentially have
led to an under-reporting of the most severe levels of depressive
symptoms (although the extent and implications of this exclu-
sion criterion are unknown, since the number of participants who
were excluded and the reasons for their exclusion were not for-
mally documented). A final limitation is that no mental health
staff were included in the implementation of the research since it
was conducted as part of the larger podoconiosis mapping study
in Rwanda.
Conclusions
Despite some limitations, our study demonstrates—to our knowl-
edge for the first time—the high levels of depressive symptoms
among people in Rwanda with lower limb lymphoedema due to
either podoconiosis or another cause. This highlights the impor-
tance of considering mental health, psychosocial and economic
interventions within MMDP packages of care, ensuring that care
for peoplewith lower limb lymphoedema is holistic andaddresses
not only the physical health consequences of the disease, but also
the mental health, psychosocial and economic outcomes.
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